


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Plozasiran for treating familial chylomicronaemia syndrome ID6593

Provisional Stakeholder List

Provisional stakeholder list for the evaluation of plozasiran for treating familial chylomicronaemia syndrome ID6593



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Salford Royal NHS Foundation Trust Mark Holland Metabolic Unit Society for Endocrinology Specialised Endocrinology Clinical Reference Group (CRG) UK Clinical Pharmacy Association University Hospital Birmingham Foundation Trust, Department of Endocrinology 	Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).


Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations

Provisional stakeholder list for the evaluation of plozasiran for treating familial chylomicronaemia syndrome ID6593

Issue date: July 2025





and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.